Yamo Pharmaceuticals LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.yamopharma.com
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Yamo Pharmaceuticals LLC
- Target Recruit Count
- 58
- Registration Number
- NCT05067582
- Locations
- 🇺🇸
Thompson Autism Center CHOC, Orange, California, United States
🇺🇸Center for Autism and The Developing Brain, White Plains, New York, United States
🇺🇸Thompson Center for Autism and Neurodevelopmental Disorders, Columbia, Missouri, United States
Safety of L1-79 in Adolescent and Adult Males With Autism
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Yamo Pharmaceuticals LLC
- Target Recruit Count
- 42
- Registration Number
- NCT02947048
- Locations
- 🇺🇸
Eric Bartky MD, Bartky Health Care Center, Livingston, New Jersey, United States
🇺🇸F. Peter Halas MD, Sea Girt Pediatrics, Sea Girt, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath